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Abstract
Purpose: In 2009 a Dutch guideline was published containing recommendations to
reduce Hospital Admissions Related to Medications (HARMs). This study aims to
examine time-trends of HARMs and their potential preventability between 2008 and
2013 in The Netherlands.
Methods: A retrospective prevalence study was conducted using the Dutch PHARMO
Database Network. A semi-automated pre-selection was used to make a crude identifi-
cation of possible HARMs of which four samples were selected. These were indepen-
dently assessed with respect to causality and potential preventability by a physician
and pharmacist. The results were stratified by age into 18-64 years and 65 years and
older. For these groups the net prevalences and incidence rates of HARMs and poten-
tially preventable HARMs were calculated for the years 2008, 2009, 2011 and 2013.
Results: Four samples of 467 (2008), 447 (2009), 446 (2011) and 408 (2013) admis-
sions were assessed. The net prevalence of HARMs in the 18-64 years group was
approximately four times smaller compared to the older group with a mean preva-
lence of 2.7% (95% confidence interval [CI]:2.4%-3.0%) and 10.2% (95%CI:
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9.7%-10.7%) respectively. The potential preventability was 25.1% (18.4%-31.8%) and
48.3% (95%CI: 44.8%-51.8%), respectively. The prevalence of HARMs in both groups
did not change significantly between 2008 and 2013 with 2.4% (95%CI: 1.9%-3.0%)
and 10.0% (95%CI: 9.0%-11.0%) in 2008 and 3.1% (2.7%-3.5%) and 10.4% (95%CI:
9.4%-11.4%) in 2013, respectively.
Conclusion: Despite efforts to reduce HARMs, the prevalence did not decrease over
time. Additional measures are therefore necessary, especially in the elderly
population.
K E YWORD S
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prevalence, side effects
1 | INTRODUCTION
Besides being beneficial, drugs can have unwanted effects which can
be mild, but can also lead to serious adverse effects, hospital admis-
sion or even death.
Hospital admissions related to medication (HARMs) are a world-
wide problem.1-9 A review published in 2016 showed a calculated
median prevalence of 6.3% of all unplanned hospital admissions in
developed countries and 5.5% in developing countries. In The Nether-
lands, one prospective and two retrospective studies have been per-
formed to estimate the prevalence of possible HARMs in 2003, 2005,
2006 and 2008.10-12 These studies have shown a prevalence of possi-
ble HARMs between 3.9 and 5.6% of acute admissions. The Quick
Assessment of Drug-Related Admissions over Time (QUADRAT) study
showed a decreasing trend of possible HARMs in The Netherlands
between 2005 (4.65%) and 2008 (3.91%).11 These results are compa-
rable to findings in other Western countries.13-15
The percentage of potentially preventable HARMs only showed a
small decreasing trend in the QUADRAT study with 20.5% in 2005
and 18.4% in 2008.11 This potential preventability was lower com-
pared to the other Dutch studies which calculated a percentage of
29,0% and 46.0%. but the QUADRAT study did not include non-
adherence as a preventable cause.10,12
To reduce the number of potentially preventable HARMs multiple
initiatives were developed and implemented. For example, educating
prescribers on medication-related patient harm has been studied.
However, no firm evidence was found to support or reject this type of
intervention according to a systematic review conducted in 2016.16 In
The Netherlands a multidisciplinary taskforce composed 40 recom-
mendations with the aim to reduce HARMs. These recommendations
were based on the most common potentially preventable HARMs
from the earlier mentioned studies10,12 and were published in
November 2009 (Dutch version).17 In the years thereafter it led to
several initiatives to reduce HARMs such as the development of clini-
cal decision support systems. Additionally checklists and toolkits were
implemented and protocols and guidelines were drafted or revised.18
These initiatives did not lead to significant improvements in the
QUADRAT study,11 but implementation of protocols and guidelines
takes time and thus this study may have come too early.
Therefore, a study was designed with the primary aim to deter-
mine whether these initiatives have led to a reduction in the preva-
lence and incidence rate of possible HARMs and potentially
preventable HARMs in The Netherlands in the years 2008 to 2013.
2 | METHODS
2.1 | Data source
For this retrospective population based prevalence study we used the
Dutch PHARMO Database Network, which combines data from dif-
ferent primary and secondary settings in The Netherlands and enables
the follow-up of more than four million residents of a well-defined
KEY POINTS
• Hospital admissions related to medication (HARM) occur
four times more often in patients of 65 years and older
compared to 18-64 years.
• 2.7% of all hospital admissions in patients between
18 and 65 years are HARMs of which 25.1% is also possi-
bly preventable.
• 10.2% of all hospital admissions in patients of 65 years
and older are HARMs of which 48.3% is also possibly
preventable.
• Between 2008 and 2013 the prevalence of HARMs did
not change over time in The Netherlands.
• Measures to reduce HARMs should focus on the preven-
tion of fractures, syncopes and GI complications in the
elderly.
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population for an average of ten years. For this study drug dispensing
data from community pharmacies and admission information of the
hospitalization Database from the Dutch Hospital Data Foundation
were used.
2.2 | Study period
To determine whether the multidisciplinary recommendations influ-
ence the number of possible HARMs the gross prevalence was calcu-
lated over the period between 2005 and 2013.17 The net prevalence
was calculated by using a sample extracted from the years 2008,
2009, 2011 and 2013. These years were chosen strategically. 2008
because the prior study investigated this year as well and we wanted
to be able to compare these methods. 2009 was included since this
was the year the HARM-Wrestling recommendations were published
in Dutch. 2011 to see whether the recommendations have led to a
decrease and this was also the year the English version of the recom-
mendations were released17 and 2013 to see whether there was a
decrease 4 years after publication of the recommendations.
2.3 | Study design
This study is a retrospective population based prevalence study. To
reduce the number needed to review in order to find a possible HARM
a triggerlist was composed using the cause for hospitalization (event)
and the concurrent drug use from the Dutch PHARMO Database Net-
work (see Supporting Information, Data S1). All admissions between
2005 and 2013 identified by the triggerlist in the Dutch PHARMO
Database Network were included to calculate the gross prevalences
and incidence rates. Patients under the age of 18 were excluded. From
the admissions included by the triggerlist a random sample was taken
for the years 2008, 2009, 2011 and 2013 in order to calculate the posi-
tive predictive value (PPV) of possible HARMs and their preventability.
2.4 | Assessment of causality and preventability
Each included admission was assessed independently by a physician
(JA/SdB/VV) and a pharmacist (FL/MW). The assessment of the cau-
sality was performed according the six axes of the algorithm of
Kramer.19 For all possibly causally associated HARMs, the potential
preventability was also assessed by applying an adjusted version of
the algorithm of Schumock and Thornton (Supporting Information,
Data S2).20 Both assessments resulted in either “yes” (possible causal
and/or potentially preventable), “no” (probably not causal and in that
case preventability not assessed) or “too little information to assess
the causality and/or preventability”. The interrater agreement was cal-
culated using the kappa statistic in IBM SPSS Statistics for Windows
version 22.0 (IBM Corporation, Armonk, USA).
In case assessments differed between the independent assessors,
consensus was reached by a final assessment performed by two
experts (medical (BS) and pharmacist (PdS/PvdB)) independently. In
case the assessments of these experts differed, consensus was
reached during a consensus meeting.
The PPV for possible causality was calculated by dividing the
number of assessed possible HARMs by the total number of admis-
sions triggered by the triggerlist. In the same way a PPV for potentially
preventability was calculated.
2.5 | Type of potentially preventable HARM
For all potentially preventable HARMs the event and associated drug
was registered. The reason for preventability was also registered.
Using the adjusted version of the algorithm of Schumock and Thorn-
ton the outcome could be one of the following: previously occurred
adverse effect; drug was inappropriate for the condition of the
patient, the dose, frequency or way of administration was inappropri-
ate for the age, weight or severity of disease of the patient, wrong
drug was dispensed, wrong drug was administrated, lack of monitor-
ing of drug or other monitoring which was required, unacceptable
drug-drug interaction, non-adherence or additional measures not
taken or inadequate (eg, lack of or ineffective dosage of gastric pro-
tection when using a Non-Steroidal Anti-Inflammatory Drugs
NSAID). Assessors were given the instructions to choose at least one
of these reasons for preventability, but could choose more if
applicable.
2.6 | Outcome measures
The primary outcome of this study was the net prevalence of poten-
tial HARMs in two age-groups: 18-64 years and 65 years and older.
This division is based on the Dutch guideline for medication reviews
(2013) which indicates to perform reviews on patients of 65 years or
older with additional risk factors. The secondary outcomes were the
incidence rate of potential HARMs, the type of HARMs and the rea-
son for potential preventability for each age-group.
2.7 | Sample size
The prevalence of HARMs identified in previous studies was 5.1%,21
5.6%,12 4.6% and 3.9%.11 When calculating the sample size the preva-
lence was estimated at 5.0% and the precision corresponding to this
effect size at 0.01. This resulted in a calculated sample size of 1825
for the random sample to be drawn for the years 2008, 2009, 2011
and 2013 from the eligible patients selected by the triggerlist.22
2.8 | Data analysis
Data from the PHARMO data record linkage (Utrecht, The Nether-
lands) were analyzed using IBM SPSS Statistics for Windows version
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22.0 (IBM Corporation, Armonk, USA). Using descriptive analysis the
crude and net prevalence including their confidence intervals were
calculated for each year.
For each age-group (18-64 and ≥ 65 years) the crude prevalence
was calculated by dividing the number of potential HARMs identified
with the triggerlist by the total number of admissions recorded in the
PHARMO record linkage system for each study year. Using the PPV
for causality the net prevalence was calculated for each age-group for
each study year. The same was done for the potential preventability,
using the PPV for preventability.
For each year between 2005 and 2013 the number of events and
the person-time of medication use were collected from the PHARMO
database using the triggerlist. The crude incidence rate was calculated
for each age-group by dividing the number of these events which indi-
cated potential HARMs by the number of years of use of the medica-
tion. These rates were adjusted for lack of supplied data. In 2008 and
2009 10% was lacking and in 2011 16%. For the year 2013 this per-
centage was unknown. Therefore the percentage of 19% from the
previous year (2012) was used. Using the PPV for causality and
preventability obtained from the sample assessment the net incidence
rate of possible causal en potentially preventable admissions were
determined.
Using the net prevalence and the total number of admissions in
the Netherlands for each age-group and year derived from Dutch
Hospital Data (DHD), the number of potentially preventable HARMs
was extrapolated to The Netherlands.
3 | RESULTS
A total of 893 593 and 750 832 admissions from the PHARMO data-
base between 2005 and 2013 could be included for age-group
1 (18-64 years) and age-group 2 (≥65 years), respectively. With the
trigger list 52 048 and 129 569 admissions were used to calculate the
gross prevalence of possible HARMs for each age-group. A sample of
1920 admissions was taken with 397 in age-group 1 and 1523 in age-
group 2. The demographic characteristics of the admissions in this
sample are shown in Table 1.
TABLE 1 Demographic characteristics of the sample
All (n = 1920) 18–64 years (n = 397) >65 years (n = 1523)
Age (y)
Mean (SD) 74.2 (14.5) 50.8 (11.7) 80.3 (7.1)
Median (Interquartile range) 78 (68-84) 54 (44-60) 81 (75-85)
Male sex 783 (40.8%) 166 (41.8%) 617 (40.5%)
Renal function
Good (MDRD >50 mL/min) 513 (26.7%) 124 (31.2%) 389 (25.5%)
Moderate (MDRD 30-50 mL/min 201 (10.5%) 17 (4.3%) 184 (12.1%)
Severe (MDRD 10-29 mL/min) 92 (4.8%) 6 (1.5%) 86 (5.6%)
Failure (MDRD <10 mL/min) 18 (0.9%) 3 (0.8%) 15 (1.0%)
Unknown 1096 (57.1%) 247 (62.2%) 849 (55.7%)
Hospital ward
Non-surgical 1426 (74.3%) 282 (71.0%) 1144 (75.1%)
Surgical 489 (25.5%) 115 (29.0%) 374 (24.6%)
Unknown 5 (0.3%) - 5 (0.3%)
Living conditions
Independently 447 (23.3%) 127 (32.0%) 320 (21.0%)
Nursing home 75 (3.9%) 5 (1.3%) 70 (2.5%)
Unknown 1398 (72.8%) 265 (66.8%) 1133 (74.4%)
Weekly dosing system
Yes 320 (16.7%) 22 (5.5%) 298 (19.6%)
No 1331 (69.3%) 284 (71.5%) 1047 (68.7%)
Unknown 269 (14.0%) 91 (22.9%) 178 (11.7%)
Reduced cognition
Yes 265 (13.8%) 105 (26.4%) 160 (10.5%)
No 235 (12.2%) 14 (3.5%) 221 (14.5%)
Unknown 1420 (74.0%) 278 (70.0%) 1142 (75.0%)
Abbreviations: MDRD, Modification of Diet in Renal Disease formula; n, number; SD, standard deviation; y, years.
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The sample of the 18-64 year group was skewed by chance with
only six hospital admissions in 2013. To calculate the prevalence of
this year the mean of the combined samples over the years of this
age-group was used.
3.1 | Interrater agreement
The interrater agreement for causality and preventability in age-group
1 was fair with a kappa value of respectively 0.24 and 0.21. For age-
group 2 the kappa values were comparable with 0.26 and 0.22 for
causality and preventability.23
3.2 | Positive predictive value of possible HARMs
and potentially preventable HARMs
The positive predictive value (PPV) for possible HARMs for age-
group 1 and age-group 2 was 45.7% (95% CI 40.7%-50.7%) and
59.3% (95%CI: 56.7%-61.9%) respectively. The PPV of potentially
preventable HARMs for age-group 1 and age-group 2 was 25.1%
(95%CI: 18.4%-31.8%) and 48.3% (95%CI: 44.8%-51.8%) respec-
tively.20 (5.0%) admissions were considered to have too little
information to assess the causality in age-group 1 and 132 (8.7%) in
age-group 2. The PPV for possible HARMs and potentially prevent-
able HARMs distributed by study year are shown in Table 2 for each
age-group.
3.3 | Prevalence of possible HARMs
The net prevalences of possible HARMs are shown in Figure 1. The
net prevalence was approximately four times smaller in age-group
1 compared to age-group 2 with a mean net prevalence of 2.7% (95%
CI:2.4%-3.0%) and 10.2% (95%CI: 9.7%-10.7%) respectively.
The net prevalence in age-group 1 did not change over the years
with 2.4% (95%CI: 1.9%-3.0%) in 2008 and 3.1% (95%CI: 2.7%-3.5%)
in 2013. In age-group 2 the net prevalence also remained similar with
TABLE 2 Positive predictive values of causality and preventability and their 95% Confidence Intervals
2008 2009 2011 2013
Causality
18–64 years 43.7% (35.1-52.3%) 46.5% (37.6-55.4%) 43.1% (34.4-51.8%) a
≥ 65 years 59.0% (53.8-64.2%) 58.8% (53.5-64.1%) 60.7% (55.4-66.0%) 57.9% (53.1-62.7%)
Preventability
18–64 years 21.7% (10.8-32.6%) 32.0% (19.3-44.7%) 23.7% (12.0-35.4%) a
≥ 65 years 49.6% (42.5-56.7%) 48.6% (41.3-55.9%) 46.8 (39.5-54.1%) 47.4% (40.8-54.0%)
aThe prevalence in 2013 was calculated with the mean positive predictive value (PPV) for the 18-64 year olds because of the skewed sample.
F IGURE 1 Net prevalences of potential and potentially preventable Hospital Admissions Related to Medication (HARMs) for each age-group.
(■: potential HARMs;▲: potentially preventable HARMs; dashed lines: 95% CI)
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10.0% (95%CI: 9.0%-11.0%) in 2008 and 10.4% (9.4%-11.4%)
in 2013.
3.4 | Prevalence of potentially preventable
HARMs
The net prevalence of potentially preventable HARMs are also shown
in Figure 1. This was 0.7% (95%CI: 0.4%-1.0%) and 4.9% (95%CI:
4.3%-5.5%) for age-groups 1 and 2 respectively and also remained
similar over the years for both age-groups.
3.5 | Incidence rates
The net incidence rates of possible HARMs for each age-group per
year are shown in Figure 2. The net incidence rates did not increase
significantly with an incidence rate of 3.26 (95%CI: 2.66-3.97) in 2008
and 3.71 (95%CI: 3.05-4.53) admissions per 10 000 person-years in
2013 for age-group 1 and an incidence rate of 12.80 (11.72-13.98)
in 2008 and 13.50 (12.42-14.69) admissions per 10 000 person-years
in 2013 in age-group 2. The incidence rates of potentially preventable
HARMs are also shown in Figure 2 and did not change over time
either.
3.6 | Types of HARMs
In Tables 3 and 4 the events and associated drug(s) are shown for
each age-group. The majority of these potentially preventable admis-
sions in the younger group were related to fractures (17.5%), hyper-
or hypoglycemia (17.5%) and gastro-intestinal (GI)-complications
(15.0%). In the older group the majority of the potentially preventable
admissions were related to fractures (30.1%), syncope/dizziness
(17.5%) and GI-complications (13.4%). In Table 5 the reasons for
potentially preventable HARMs are shown for each age-group. In age-
group 1 the most frequent reason for potential preventability was that
additional measures were not taken or were inadequate (39.0%). In
age-group 2 the main reason was that the dose, frequency or way of
administration was inappropriate for the age, weight or severity of
disease of the patient.
3.7 | Extrapolation to the Dutch population
We observed an increase of almost 6000 admissions in the absolute
number of possible HARMs in age-group 1 from 11 409 (95%CI:
8934-13 990) in 2008 to 17 161 (95%CI: 14 907-19 508) in 2013. In
the second age-group a larger increase of approximately 10 000
admissions was found, from 38 739 (95%CI: 34 794-42 786) in 2008
to 48 779 (95%CI: 44 119-53 550) in 2013.
The number of potentially preventable HARMs in age-group
1 increased from 2475 (95%CI: 965-4 561) in 2008 to 4307 (95%CI:
2743-6 203) admissions in 2013, and from 19 214 (95%CI:
14 787-24 260) in 2008 to 23 121 (95%CI: 18 000-28 917) admis-
sions in 2013 admissions in 2013 in age group 2.
4 | DISCUSSION
This study showed the prevalence of hospital admissions related to
medication (HARMs) to be stable between 2008 and 2013, both for
F IGURE 2 Net incidence rates of possible and potentially preventable Hospital Admissions Related to Medication (HARMs) for each age-
group. (■: potential HARMs;▲: potentially preventable HARMs; dashed lines: 95% CI)
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patients between 18 and 65 years as for patients of 65 years and
older. The incidence rate also remained constant in both age-groups.
Since the total number of hospital admissions in The Netherlands
increased with 20% (18-64 years) and 21% (> 65 years) between
2008 and 2013 the absolute number of potential HARMs in The
Netherlands also increased with approximately 6.000 (18-64 years)
and 10.000 (> 65 years) admissions. The associated numbers of
potentially preventable HARMs increased by approximately 1.800
(18-64 years) and 4.000 (> 65 years) admissions.
A review from 2016 which included 30 studies from developed
countries showed a median prevalence of HARMs of 6.3% (IQR
3.3-11.0).2 This corresponds to the mean of the prevalences of the
two age-groups. Our study is the first to investigate the number of
possible HARMs for two age-groups whichshows the prevalence in
the >65 group to be approximately four times higher with a mean
prevalence of 10.2% compared to 2.7% in the 18-64 group. This is as
expected since older people have more comorbidities and therefore
use more drugs which increases the risk of HARMs.12 This confirms
recommendations from previous studies that initiatives to reduce
HARMs should be especially targeted on patients of 65 years and
older.10-12,17
By analyzing two age-groups we could also show the difference
in reason for admission, related drugs and reason for preventability.
Fractures are responsible for most HARMs in both groups (18-64y:
17.5%; >65y: 30.1%) and GI-complications has the third place in both
groups. The second most frequently occurring HARM however differs
with hyper- or hypoglycemia in the younger group and syncope/ dizzi-
ness/ hypotension/ collapse in the older group. This shows that differ-
ent age-groups need different attention when trying to reduce the
number of HARMs.
By investigating multiple years we could follow the trend of
potential HARMs over multiple years. This showed no increase or
decrease. The HARM-Wrestling recommendations were based on the
HARM- and IPCI study which were also included in this study, but this
study also included a number of types of HARMs which were not
included in previous studies. This could be the reason why a clear
effect of efforts taken to reduce the number of HARMs was not seen
in this study since these efforts were not targeted on the new types
of HARMSs. In the QUADRAT study bleeding outside the GI tract,
serious GI events, and constipation due to ileus had the highest
PPVs.11 As stated earlier GI complications were found as the third
most frequent event in both age-groups. In this study fractures was
the most frequent event in both age-groups due to predominantly
benzodiazepines. This type of HARM was included in the QUADRAT
study but did not show the same results. This is because the recom-
mendation to avoid benzodiazepines (especially in elderly) was
assessed more strictly in this study.
As stated before a major strength of this study is the stratification
of the results by age. Other strengths are the large number of patients
included and the robust method of analysis. However, this study also
has several limitations. First, the random sample included visits to the
emergency department which did not lead to an admission. These
TABLE 3 Types of potential HARMs and associated drugs in patients between 18 and 65 years
Event category Events in category
Number of potentially
preventable HARMs (%)
Associated drugs (more than one was
possible)
Fractures low- (3) and high impact (4)
fractures
7 (17.5%) Benzodiazepines (6), GABA-receptor
agonist (1), SSRI (1), Flufenazine (1)
Hyper- or hypoglycemia Keto-acidosis (5), hypoglycemia (2) 7 (17.5%) insulins (7)
GI-complications GI-bleeding (6) 6 (15%) TAIs (3), VKAs (3) NSAIDs (3),
dipyridamol (1)
Ileus/obstipation Obstipation/Ileus 4 (10%) Opioids (3), mebeverin (1)
Electrolytes disorder Hypo-osmolality (2), hypovolemia
(1)




hypotension (1), syncope (2) 3 (7.5%) RAS-inhibitors (1), thiazide diuretics (1),
nitrates (1),
dihydropyridinederivatives (1),
selective beta blockers (1)
Bleeding (other than GI-tract) Chronic blood loss (2) 2 (5%) TAIs (2), VKAs (1)
Respiratory disorder Asthma (1), Other lower
respiratory disorders (2)
2 (5%) Benzodiazepines (1), selective beta2
sympathomimetic (1)
Central nervous system Epilepsy (1), migraine (1) 2 (5%) SSRI (1), NSAID (1), Opioid (1)




Abbreviations: GABA, Gamma-Aminobutyric acid; GI, Gastrointestinal; HARM, Hospital Admission Related to Medication; NSAID, Nonsteroidal anti-
inflammatory drug; RAS, Renin-angiotensin system; SSRI, Selective serotonin reuptake inhibitor; TAI, Thrombocyte aggregation inhibitor; VKA, Vitamin K
antagonist.
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admissions were not excluded from the sample because the overall
PHARMO data linkage included these visits as well. By including these
emergency department visits in the numerator as well as the denomi-
nator the number of admissions was corrected. Second, the interrater
agreement between the first assessors which consisted of a physician
and a pharmacist was fair for possible causality as well as for the
potential preventability.23 This is less than what we aimed to achieve
since the interrater agreement in the QUADRAT study was also insuf-
ficient. However, as we used consensus methodology, this limitation
did not influence our results. Third, the preselection of possible
HARMs was based on the event and drug used according to the dis-
pensing data of community pharmacies. However, medication admin-
istered in the hospital (ie, chemotherapy) and over the counter
medications are not registered and thus cannot be taken into account
when calculating the prevalence of possible HARMs. This means the
results of this study provide an underestimation of reality. Fourth, it is
unknown whether other alterations besides the HARM-Wrestling rec-
ommendation could have influenced the prevalence such as the
implementation of other guidelines. Finally, the letters of discharge
which were assessed varied substantially in content from highly
TABLE 4 Types of potential HARMs and associated drugs in patients of 65 years and older
Event category Events in category
Number of potentially
preventable HARMs (%)
Associated drugs (more than one was
possible)
Fractures Pathological (3), low- (73) and high
impact (34) fractures
110 (30.1%) Benzodiazepines (96), opioids (10),
thiazide diuretics (8), SSRIs (6),
antipsychotics (6), other
antidepressants (5), mirtazapine (5),
glucocorticoid (3), dementia (2),
selective beta blockers (2), RAS-
inhibitors (2), urologic spasmolytic
(2), atypical antipsychotics (2)
Syncope/ dizziness/
hypotension/ collapse
Dizziness (3), hypotension (6), syncope
(55)
64 (17.5%) RAS-inhibitors (46), thiazide diuretics
(25), nitrates (20),
dihydropyridinederivatives (16),
selective beta blockers (10), digoxin
(7), benzodiazepines (6), Lis
diuretics (4), diltiazem (3), non-
selective beta blockers (3), alpha-
and beta blockers (3), SSRIs (3),
opioids (2), spironolactone (2)
GI-complications Gastro-duodenal ulcers (5), gastritis
(2), GI-bleeding (42)
49 (13.4%) TAIs (32), VKAs (17), NSAIDs (11),
coxibs (2)
Bleeding (other than GI-
tract)
Anemia (12), cerebral bleeding (10),
nose bleeding (2), internal bleeding
(2), urinal bleeding (1)
27 (7.4%) TAIs (16), VKAs (14)
Electrolytes disorder Hypo-osmolality (9), hypovolemia (14),
hyperkalemia (4)
27 (7.4%) Lis diuretics (13), thiazide diuretics
(12), Potassium saving drugs
(14),RAS-inhibitors (5), SSRsI (2)
Hyper- or hypoglycemia Hypoglycemia 21 (5.7%) Sulfonylurea derivatives (14), insulins
(7)
Ileus/obstipation Obstipation/Ileus 17 (4.6%) Opioids (11),
dihydropyridinederivatives (5),
ferritins (4), TCAs (2), loperamide
(2), serotonin-antagonists (2)
Heart failure Congestive heart failure 14 (3.8%) NSAIDs (9), diltiazem (3),
glucocorticoids (2),
thiazolidinedione's (2)
Respiratory disorder Asthma (1), Other lower respiratory
disorders (4)
5 (1.4%) Benzodiazepines (4), selective beta
blocker (1)
Kidney disorder Acute renal failure 5 (1.4%) RAS-inhibitors (5), spironolactone (3),
thiazide diuretics (1),
Heart rhythm disorder Atrial fibrillation 4 (1.1%) Verapamil (2)
Fever/infection Urinary tract infection 2 (0.5%) Urologic spasmolytic (2)
Abbreviations: GI, Gastrointestinal; HARM, Hospital Admission Related to Medication; NSAID, Nonsteroidal anti-inflammatory drug; RAS, Renin-
angiotensin system; SSRI, Selective serotonin reuptake inhibitor; TAI, Thrombocyte aggregation inhibitor; TCA, Tricyclic antidepressants; VKA, Vitamin K
antagonist.
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detailed to almost no information about the reason for admission. This
resulted in a high number of admissions which could not be assessed.
Despite these limitations, this study adds to our knowledge on
medication related hospital admissions. It showed that efforts taken
by healthcare providers may have contributed to a stable number of
HARMs, but further efforts are needed. The preventive measures and
initiatives developed up to now are shown insufficient to reduce the
prevalence of HARMs.
To decrease the number of HARMs multidisciplinary initiatives are
needed. The first recommendation is to further implement the protec-
tive measures, but also to be strict in upholding the national and inter-
national guidelines. For example to be strict in not prescribing
benzodiazepines to older patients, especially not during a long period of
time. The use of this drug was intended for a short period of time.24
The second recommendation is to further improve our pharmacy and
physician prescribing systems. These systems should facilitate the pro-
tective measures and monitoring recommended in the guidelines A
third recommendation is to train emergency personnel to identify a
HARM in order to give the right care. In almost none of the admissions
included in the sample the doctor suspected a HARM. Support from an
emergency pharmacist may assist in improving this identification.
Finally, implementation studies are needed in order to identify facilita-
tors and barriers for implementation of the protective measures.
In conclusion, the prevalence and incidence rate of potential
HARMs and potentially preventable HARMs remain stable between
2008 and 2013. Furthermore, to prevent HARMs more initiatives
should especially target older patients (65 years and older) since they
have a four times higher prevalence of potential HARMs than younger
patients (18-64 years). These measures should focus on the preven-
tion of fractures, syncopes and GI complications since these events
have the highest prevalence of potentially preventable HARMs among
older patients.
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